Moreover, a retrospective real-world study shows that both GLP1-RA and SGLT-2 inhibitors reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention [17], although SGLT-2 inhibitors seem to have a greater cardioprotective benefit compared to GLP-1RA when used for secondary prevention among adults with T2D [18]. Here, SLC5A2 is linked to cardiovascular disorder.